Cannabis Science Updates Second Medical Cannabis Cancer Patient Suffering from Squamous Cell Carcinoma Photo-documents Cannabis Extracts Killing Cancerous Tumor

January 19, 2012

DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is very pleased to announce that the second patient suffering from basal cell carcinoma (skin cancer) has self-administered cannabis extracts that appear to have eradicated the cancer.

Following up on the December 12, 2011 news release regarding a second cancer patient self-administering cannabis extract, this patient has now given the photo-documented dramatic results of treatment process. These images can be viewed on the www.cannabisscience.com website. While the treatment has been completed and the cancer seems to be gone, Cannabis Science is waiting for a full biopsy report from the physician to confirm the patient is free of cancer cells.

Currently it appears that the aforementioned patient will be able to avoid any surgical procedures such as, standard surgical excision (Mohs Surgery), and other various types of treatment for skin cancer, like chemotherapy, radiation, and cryosurgery, by using the cannabis extracts, just like the first patient mentioned in our March 9, 2011 news release.

While other treatment options may be effective for many, few patients would choose to go through a surgical procedure, and endure the side effects of radiation, or chemotherapy if a simpler and safer alternative were available. Patients self-administering cannabis extracts in the convenience of their own home appear to be effectively resolving their cancerous lesions over a period of a few weeks to a few months.

Cannabis Science is committed to making cannabis-based medicines available to the public as rapidly as possible. The Company is taking multiple approaches to accomplishing this aim in the United States. The science of cannabinoids has exploded over the past decade, laying the scientific foundation for the many medicinal uses of this unique plant. Endoannabinoids are a class of biologically active lipid compounds produced by all vertebrates (endocannabinoids) the Cannabis plant (phytocannabinoids), and more recently patentable synthetic compounds produced by chemists. Today’s modern peer-reviewed science supports the many historical uses that were discovered over thousands of years of medicinal use by herbalists.

Please visit www.cannabisscience.com to view the “Breaking News” of the successful results and images of the self-administered cancer treatments.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contacts
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
Investor Relations Management
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cannabisscience.com